<DOC>
	<DOCNO>NCT02458235</DOCNO>
	<brief_summary>The goal study determine whether post-transplant consolidation azacitidine combine donor lymphocyte infusion ( DLI ) safe effective approach prevention relapse pediatric young adult patient hematologic malignancy undergo hematopoietic stem cell transplantation ( HSCT ) .</brief_summary>
	<brief_title>Donor Lymphocyte Infusion With Azacitidine Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation</brief_title>
	<detailed_description>This phase II single-arm trial azacitidine ( IV SC ) combination escalate donor lymphocyte infusion ( DLI ) . Patients enrol study day +28 +/- 7 post-transplant , prior withdrawal immunosuppression administration donor lymphocyte infusion ( DLI ) . They donor chimerism minimal residual disease ( MRD ) test peripheral blood ( PB ) bone marrow ( BM ) day +28 Â± 7 . Patients stratify accord risk category ( low , standard high ) , define GVHD status , mixed versus full donor chimerism , positive versus negative MRD result . Depending risk assessment , immunosuppression taper accord standard fast schedule , patient ( exception low-risk ALL patient ) receive one cycle low-dose azacitidine ( 40mg/m2 IV/SC daily x 4 day ) . After taper immunosuppression , chimerism repeat patient receive 6 additional cycle low-dose azacitidine , depend risk assessment . For patient meet criterion high risk relapse , azacitidine combine escalate dos DLI maximum 7 cycle total . Risk safety assessment , include routine laboratory parameter , donor chimerism , minimal residual disease , GHVD activity assess follow cycle . Chimerism minimal residual disease test repeat every cycle peripheral blood ( PB ) , bone marrow ( BM ) test every cycle . Patients follow laboratory monitoring physician evaluation prior cycle , follow two year post-transplant study toxicity GVHD outcome .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients age 0 29.9 year undergo allogeneic peripheral blood stem cell transplant Patients acute myelogenous leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) Patients juvenile myelomonocytic leukemia ( JMML ) Patients myelodysplastic syndrome ( MDS ) Patients prior transplant . Patients Fanconi anemia cancerpredisposition syndromes Patients expect survival &lt; 12 week Lansky score &lt; 60 %</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>pediatric leukemia myelodysplastic syndrome azacitidine</keyword>
</DOC>